In a large, rigorously matched cohort, GLP-1RA therapy was associated with a reduced risk of TED diagnoses, surgeries, and systemic steroid use compared to other glucose-lowering medications. These findings suggest a potential protective role for GLP-1 signaling in modulating orbital inflammation, though prospective trials are required for confirmation.
Muayad et al. (Wed,) studied this question.